Ann: Race Develops Improved IV Formulation of Zantrene, page-11

Wow Guys!

I was just flicking through today’s ASX ANNs & came across this one.

This is a very positive & significant announcement for you all. Congratulations

Just from a nursing perspective (and I hope this is helpful information) not only to be able to be given via a peripheral IV cannula, but a lot of oncology patients are treated via infusers at home now, which run over a period of time continuously via a PICC line (which is still classed a CVC, but inserted peripherally & the tip sits in the large veins above the heart, same as central line). The reason being is they last longer than a cannula & less likely to be dislodged or tissue. IVCs need to be changed every 3 days, but of course if it’s just for a day infusion visit to an outpatient department, it’s inserted & removed before the patient goes home.

Far more convenient, less invasive & less infection risk than a CVC.

Some information on Infusers here:

https://www.eviq.org.au/getmedia/fcbc56ad-49fe-4e79-95bd-ce8209a300d5/502-elastomeric-Infusion-system-Pt-info.pdf.aspx?ext=.pdf

I really don’t know if that would be relative to how Zantrene is administered (over time)? but I thought you might find this interesting & certainly gives far more convenience & options for Oncologists & patients receiving chemo in the home. Biotech investing is such a process & takes a lot of patience, it’s great to get good news & I hope that is reflected in your SP today.

Well done RAC & GLTAH